The European patent office EPO has announced its intention to grant another European patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled “Method for designing an individually customized implant” relates to Episurf Medical’s individualised Episealer® Femoral Twin joint implant and its design process.

“This patent forms a part of our overall IP protection in Europe for the company’s implant technology, and gives protection in the field of patient-specific implant design based on medical imaging”, comments Katarina Flodström, COO, Episurf Medical.

CisionBlockPro\Cision\FeedItem Object
(
    [HtmlCompanyInformation:protected] => <p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><strong><span style="font-size:10pt">About Episurf Medical</span></strong></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><span style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CEST on 19 April 2022.</em></span></p>
    [HtmlContact:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><strong><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">For more information, please contact:</span></strong></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">P&aring;l Ryfors, CEO, Episurf Medical<br /></span><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">Tel:</span><span style="font-size: 10pt;">+46 (0) 709 62 36 69<br /></span><span style="font-size: 10pt;">Email:&nbsp;</span><a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></p>
    [HtmlTitle:protected] => <h1 style="line-height:120%"><span style="font-family:arial,helvetica,sans-serif"><strong>New European patent approval for Episurf Medical</strong></span></h1>
    [HtmlHeader:protected] => 
    [HtmlIntro:protected] => 
    [Body:protected] => The European patent office EPO has announced its intention to grant another European patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled “Method for designing an individually customized implant” relates to Episurf Medical’s individualised Episealer® Femoral Twin joint implant and its design process.
“This patent forms a part of our overall IP protection in Europe for the company’s implant technology, and gives protection in the field of patient-specific implant design based on medical imaging”, comments Katarina Flodström, COO, Episurf Medical.
    [HtmlBody:protected] => <p style="margin-bottom:11px;margin-top:12px"><span style="font-size:10pt"><span style="font-family:arial,helvetica,sans-serif">The European patent office EPO has announced its intention to grant another European patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled “<em>Method for designing an individually customized implant</em>” relates to Episurf Medical’s individualised Episealer® Femoral Twin joint implant and its design process. </span></span></p>
<p style="margin-bottom:11px"><span style="font-size:10pt"><span style="font-family:arial,helvetica,sans-serif">“<em>This patent forms a part of our overall IP protection in Europe for the company’s implant technology, and gives protection in the field of patient-specific implant design based on medical imaging</em>”, comments Katarina Flodström, COO, Episurf Medical.</span></span></p>
    [ServiceCategories:protected] => Array
        (
            [0] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => EU Transparency SE
                    [Name:protected] => SeFsaCategoryCode
                    [Value:protected] => S6
                )
            [1] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => OMX Filing (OMX CNS)
                    [Name:protected] => OMX CategoryCode
                    [Value:protected] => 428
                )
            [2] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => Twitter
                    [Name:protected] => Twitter
                    [Value:protected] => 9341
                )
            [3] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => LinkedIn
                    [Name:protected] => LinkedIn
                    [Value:protected] => 12311
                )
            [4] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => Facebook
                    [Name:protected] => Facebook
                    [Value:protected] => 14035
                )
        )
    [LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
    [CompanyInformation:protected] => About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CEST on 19 April 2022.
    [Contact:protected] => For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
    [Header:protected] => 
    [Keywords:protected] => Array
        (
            [0] => Episurf Medical
            [1] => EpiSurf
            [2] => Episealer
        )
    [QuickFacts:protected] => Array
        (
        )
    [Categories:protected] => Array
        (
        )
    [Videos:protected] => Array
        (
        )
    [Files:protected] => Array
        (
            [0] => CisionBlockPro\Cision\File Object
                (
                    [IsMain:protected] => 1
                    [MediaType:protected] => File
                    [Url:protected] => https://mb.cision.com/Main/14691/3547474/1565188.pdf
                    [FileName:protected] => wkr0006.pdf
                    [Title:protected] => New European patent approval for Episurf Medical
                    [Description:protected] => New European patent approval for Episurf Medical
                    [CreateDate:protected] => 2022-04-19T06:30:03.177Z
                    [Keywords:protected] => Array
                        (
                        )
                    [Extension:protected] => pdf
                )
        )
    [Quotes:protected] => Array
        (
        )
    [ExternalLinks:protected] => Array
        (
        )
    [EmbeddedItems:protected] => Array
        (
        )
    [Id:protected] => 4239542
    [EncryptedId:protected] => 513321B65559DC06
    [IsRegulatory:protected] => 1
    [PublishDate:protected] => 2022-04-19T06:30:00Z
    [LastChangeDate:protected] => 2022-04-19T06:30:03.16Z
    [Title:protected] => New European patent approval for Episurf Medical
    [Intro:protected] => 
    [IptcCode:protected] => 04016003
    [InformationType:protected] => PRM
    [LanguageCode:protected] => en
    [CountryCode:protected] => se
    [CanonicalUrl:protected] => 
    [CisionWireUrl:protected] => https://news.cision.com/episurf/r/new-european-patent-approval-for-episurf-medical,c3547474
    [LanguageVersions:protected] => Array
        (
        )
    [Images:protected] => Array
        (
        )
    [Tickers:protected] => Array
        (
            [0] => stdClass Object
                (
                    [Symbol] => EPIS B
                    [ISIN] => SE0003491562
                    [PrimaryListing] => 1
                    [IsShare] => 1
                    [MarketPlaceSymbol] => STO
                    [MarketPlaceName] => Stockholmsbörsen
                    [MarketPlaceBloombergCode] => SS
                    [MarketPlaceMarketWireCode] => OMX
                    [MarketPlaceIsRegulated] => 1
                    [MarketPlaceCountryCode] => SE
                )
        )
)